Welcome to our dedicated page for ACOR news (Ticker: ACOR), a resource for investors and traders seeking the latest updates and insights on ACOR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ACOR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ACOR's position in the market.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) has completed the sale of its manufacturing operations in Chelsea, Massachusetts to Catalent for $80 million, yielding net proceeds of approximately $74 million. This agreement includes a long-term global supply contract, allowing Catalent to manufacture and package Acorda's drug INBRIJA, ensuring quality and consistency in supply for patients. Acorda offers therapeutics for neurological disorders, including INBRIJA for Parkinson’s disease and AMPYRA for multiple sclerosis.
Acorda Therapeutics (Nasdaq: ACOR) has agreed to sell its INBRIJA manufacturing facility to Catalent for $80 million, netting approximately $70 million after expenses. This transaction includes a long-term supply agreement for INBRIJA, ensuring continued access for patients. Acorda is restructuring to reduce costs, anticipating $40 million in savings, and will cut its workforce by 16%. Expected Q4 2020 revenue for INBRIJA is around $9 million, while AMPYRA's revenue is approximately $25 million. The company is also launching an At The Market offering worth $15.25 million for additional financing.
Acorda Therapeutics (NASDAQ: ACOR) announced that CEO Ron Cohen will present at the 39th Annual J.P. Morgan Health Care Conference on January 14 at 5:20 PM ET. A live audio webcast of the presentation will be available on the Acorda website under 'Investor Events'. Acorda develops therapies for neurological disorders, including INBRIJA® for Parkinson's disease OFF episodes and AMPYRA® for multiple sclerosis. The company highlights potential risks associated with its operations and products, which may impact performance and future prospects.
Acorda Therapeutics (NASDAQ: ACOR) will present at the H.C. Wainwright BIOCONNECT Virtual Conference from January 11th to 14th, 2021. CEO Ron Cohen, M.D., will lead the presentation, accessible via an audio webcast on the Acorda website. Acorda specializes in developing therapies for neurological disorders, with products like INBRIJA® for Parkinson's disease and AMPYRA® for multiple sclerosis. The company highlights forward-looking statements regarding its market operations and product developments, underscoring potential risks including competition and regulatory challenges.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) has completed a 1-for-6 reverse stock split effective January 4, 2021, to comply with Nasdaq's minimum bid price requirement of $1.00. Following this split, 370 million shares have been reduced to approximately 61.67 million. Each stockholder now owns the same percentage of shares as before but in a smaller quantity. The company aims to enhance its market position amid ongoing challenges, including competition and regulatory hurdles affecting its products, notably INBRIJA for Parkinson’s disease treatment.
Acorda Therapeutics reported its Q3 2020 financial results, showcasing a 24% increase in INBRIJA net sales to $5.8 million, compared to $4.9 million in Q3 2019. AMPYRA revenue decreased to $27.3 million from $39.3 million in the same period a year prior. The company received a $15 million milestone payment from Biogen, enhancing its financial position. Acorda’s GAAP net income improved to $7.3 million, contrasting with a $263.5 million loss in Q3 2019. The company expects AMPYRA revenue for 2020 to be between $85 - $110 million.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast on November 3, 2020, at 4:30 p.m. ET to discuss its third quarter 2020 update and financial results. Participants must pre-register via a designated link to join the call. A replay will be available starting at 7:30 p.m. ET on the same day until December 3, 2020. Acorda continues to develop therapies for neurological disorders, including INBRIJA and AMPYRA. The company cautions that various risks may impact its future performance and product sales.